Why Healthcare?

Hey guys,

I know I'm going to get heat for this, but why would someone choose to go into healthcare investment banking? I know it's one of those industries that will continue, but the volatility and unpredictability seems to be a deterrent.

Any info will help.

 
Best Response
  • Active M&A environment centered around cost-managing and pricing leverage (merging hospital systems, PBM, biotech/pharma, insurance, e.g. Shire-Baxalta, Pfizer-Allergan, Aetna-Humana, Anthem-Cigna, UNH-Catamaran, the list goes on...)
  • Cost savings and operating efficiencies from consolidation of EMR/EHR platforms and emergent info tech
  • New and life-altering treatments are being developed for previously-economically-unfeasible drugs for rare diseases (Shire-Baxalta)
  • "Panacea" drugs with much greater effectiveness and safety profile for patients (adalimumab, sofosbuvir, etc)
  • Further fundamental changes in value model of drug development (Allergan, Valeant, etc)
  • Leveraging population health implementation brings challenges, promises huge value (Optum/UNH, etc)
  • Breeding ground for new technology and new models for Incentivizing human behavior to improve care and generate value (e.g. servicing noncompliant patient populations)

Massive industry disruptions are generally a good thing for investment bankers.

 
Solidarity:

- Active M&A environment centered around cost-managing and pricing leverage (merging hospital systems, PBM, biotech/pharma, insurance, e.g. Shire-Baxalta, Pfizer-Allergan, Aetna-Humana, Anthem-Cigna, UNH-Catamaran, the list goes on...)
- Cost savings and operating efficiencies from consolidation of EMR/EHR platforms and emergent info tech
- New and life-altering treatments are being developed for previously-economically-unfeasible drugs for rare diseases (Shire-Baxalta)
- "Panacea" drugs with much greater effectiveness and safety profile for patients (adalimumab, sofosbuvir, etc)
- Further fundamental changes in value model of drug development (Allergan, Valeant, etc)
- Leveraging population health implementation brings challenges, promises huge value (Optum/UNH, etc)
- Breeding ground for new technology and new models for Incentivizing human behavior to improve care and generate value (e.g. servicing noncompliant patient populations)

Massive industry disruptions are generally a good thing for investment bankers.

wow sir, this is most useful. we should have such a post for every coverage group.
 
Solidarity:

- Active M&A environment centered around cost-managing and pricing leverage (merging hospital systems, PBM, biotech/pharma, insurance, e.g. Shire-Baxalta, Pfizer-Allergan, Aetna-Humana, Anthem-Cigna, UNH-Catamaran, the list goes on...)
- Cost savings and operating efficiencies from consolidation of EMR/EHR platforms and emergent info tech
- New and life-altering treatments are being developed for previously-economically-unfeasible drugs for rare diseases (Shire-Baxalta)
- "Panacea" drugs with much greater effectiveness and safety profile for patients (adalimumab, sofosbuvir, etc)
- Further fundamental changes in value model of drug development (Allergan, Valeant, etc)
- Leveraging population health implementation brings challenges, promises huge value (Optum/UNH, etc)
- Breeding ground for new technology and new models for Incentivizing human behavior to improve care and generate value (e.g. servicing noncompliant patient populations)

Massive industry disruptions are generally a good thing for investment bankers.

I assume the Insurance mergers will fall under FIG and not Healthcare?

 

not a banker, but we have a lot of clients in healthcare. a couple reasons make this an attractive industry:

  1. plenty of venture money interested in it, so early companies with interesting compounds/delivery methods will have capital available to them, so that takes care of early stage

  2. FDA is becoming very friendly to innovative drugs that cure a lot of diseases, like immunotherapies

  3. mature companies that own the molecules have cash to make acquisitions

  4. marketers generate tons of free cash flow to make acquisitions once the drugs become marketable

  5. pharma got really fat over the past 2 decades, but it has recently gotten leaner, with companies getting more focused, spinning off divisions, etc. this goes in waves, expect that cycle to continue.

 

Ut veritatis et vel fugit optio libero. Quia sapiente distinctio rerum cupiditate quia. Nihil amet veniam expedita officia iusto.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
GameTheory's picture
GameTheory
98.9
7
dosk17's picture
dosk17
98.9
8
kanon's picture
kanon
98.9
9
Jamoldo's picture
Jamoldo
98.8
10
DrApeman's picture
DrApeman
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”